Skip to main content
SpringerLink
Log in

New Thrombolytic Strategy: Bolus Administration of tPA and Urokinase-Fibrinogen Conjugate

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Increased efficacy of thrombolytic therapy requires a comprehensive search for new and novel therapeutic strategies. Many new modified forms of plasminogen activators have been obtained by means of chemical and biological synthesis. However, clinical findings demonstrate that the reperfusion level achieved during thrombolysis remains the same for various thrombolytic agents, irrespective of an extensive search for an “ideal” thrombolytic. Thrombolytic therapy may be complicated by treatment delays, cumbersome schemes of preparation and administration, and hemorrhagic and rethrombotic events. These limitations may be overcome, at least in part, by applying combined thrombolysis with plasminogen activators exhibiting complementary actions and different pharmacokinetic profiles. The combined action of native thrombolytics allows the use of lower doses and simplified schemes of administration, yielding encouraging results in experimental models. Long-acting forms of plasminogen activators are being developed and tested in combination with tissue-type plasminogen activator as a trigger of thrombolysis. The combination of short- and long-acting plasminogen activators appears promising and potentially eligible for bolus administration to patients. On the basis of our own experimental results and data in the literature, we suggest a new thrombolytic strategy connected with the single injection of a combination of complementary and pharmacokinetically different plasminogen activators.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Marder VJ, Sherry S. Thrombolytic therapy: Current status. N Engl J Med 1988;318:1512–1520.

    Google Scholar 

  2. Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. N Engl J Med 1993;329:703–709.

    Google Scholar 

  3. Maksimenko AV. Molecular interactions during fibrinolysis. Search for new plasminogen activators. Molecular Biology [in Russian] 1995;29:38–60, Engl transl 20–31.

    Google Scholar 

  4. Haber E., Quertermous T., Matsueda GR. Runge MS. Innovative approaches to plasminogen activator therapy. Science 1989;243:51–56.

    Google Scholar 

  5. Becker RC. Thrombolytic agents and anticoagulants. Cardiovasc Drug Ther 1993;7:825–828.

    Google Scholar 

  6. Collen D. Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation 1996;93:857–865.

    Google Scholar 

  7. Dewerchin M, Collen D. Enhancement of the thrombolytic potency of plasminogen activators by conjugation with clotspecific monoclonal antibodies. Bioconjugate Chem 1991;2: 293–300.

    Google Scholar 

  8. Maksimenko AV. Mutant and hybrid protein derivatives for experimental therapy using plasminogen activators. Khim Farm Zhurnal [in Russian] 1994;28:4–11, Engl transl 293–302.

    Google Scholar 

  9. Hayzer DJ, Lubin IM, Runge MS. Conjugation of plasminogen activators and fibrin-specific antibodies to improve thrombolytic therapeutic agents. Bioconjugate Chem 1991; 2:301–308.

    Google Scholar 

  10. Maksimenko AV, Torchilin VP. Water-soluble urokinase derivatives with increased affinity to the fibrin clot. Thromb Res 1985;38:289–295.

    Google Scholar 

  11. Maksimenko AV, Samarenko MB, Petrov AD, Tischenko EG, Ruda MY, Torchilin VP. Fibrinogen immobilized urokinase demonstrates increased thrombolytic activity in animal experiments. Ann NY Acad Sci 1990;613:479–482.

    Google Scholar 

  12. Atkins P, Hawkins A. Diagnosis of deep venous thrombosis of the leg using 125I-fibrinogen. Br J Surg 1968;55:825–830.

    Google Scholar 

  13. Browse NL. The 125I-fibrinogen uptake test. Arch Surg 1972;104:160–163.

    Google Scholar 

  14. Krohn KA, Knight LC. Radiopharmaceuticals for thrombus detection: Selection, preparation and critical evaluation. Semin Nucl Med 1977;7:219–228.

    Google Scholar 

  15. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982;257: 2912–2919.

    Google Scholar 

  16. Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989;14:1566–1569.

    Google Scholar 

  17. Collen D, Stassen JM, De Cock F. Synergistic effect of thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model. Thromb Haemost 1987;58:943–946.

    Google Scholar 

  18. Fleury V, Loyan S, Lijnen HR, Nieuwenhuizen W, Angles-Cano E. Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface. Eur J Biochem 1993;216:549–556.

    Google Scholar 

  19. Grailhe P, Nieuwenhuizen W, Angles-Cano E. Study of tissue-type plasminogen activator binding sites on fibrin using distinct fragments of fibrinogen. Eur J Biochem 1994;219: 961–967.

    Google Scholar 

  20. Sakharov DV, Rijken DC. Superficial accumulation of plasminogen during plasma clot lysis. Circulation 1995;92: 1883–1890.

    Google Scholar 

  21. Sakharov DV, Nagelkerke JF, Rijken DC. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. J Biol Chem 1996;271:2133–2138.

    Google Scholar 

  22. Pannel R, Black J, Gurevich V. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. J Clin Invest 1988;81:853–859.

    Google Scholar 

  23. Gurevich V. Experiences with pro-urokinase and potentiation of its ~brinolytic effect by urokinase and by tissue plasminogen activator. J Am Coll Cardiol 1987;10(Suppl. B): 16B–21B.

    Google Scholar 

  24. Maksimenko AV. Experimental combined thrombolytic therapy: Current state and trends of development. Khim Farm Zhurnal [in Russian] 1994;28:3–13, Engl transl 867–878.

    Google Scholar 

  25. Maksimenko AV, Tischenko EG, Petrov AD, Petrova ML. Effective enzyme thrombolytic composition on the base of wild-type and chemically modified plasminogen activators. Ann NY Acad Sci 1996;799:146–150.

    Google Scholar 

  26. Jou B-S, Bjornsson TD. Simultaneous determination of free tissue-type and free urokinase-type plasminogen activators in biological fluids by a solid-phase immunoassay. Anal Biochem 1993;209:70–78.

    Google Scholar 

  27. Bugge TH, Flick MJ, Danton MJS, et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996;93:5899–5904.

    Google Scholar 

  28. Carmeliet P, Moons L, Herbert JM, Crawley J, Lupu F, Lijnen R, Collen D. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in nice. Circ Res 1997;81:829–839.

    Google Scholar 

  29. Maksimenko AV, Tischenko EG, Dobrovolsky AB, Golubykh VL. Conjunctive thrombolysis under the action of tissue-type plasminogen activator and conjugate urokinase-fibrinogen after double sequential bolus administration in the model of vein thrombosis in dogs. Fibrinolys Proteolys 1998;12:45–52.

    Google Scholar 

  30. Popma JJ, Califf RM, Ellis SG, et al. Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: A quantitative angiographic and hematologic study. J Am Coll Cardiol 1992;20:1305–1312.

    Google Scholar 

  31. Collen D, Stump DC, Van deWerf F. Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents. Am Heart J 1986;112:1083–1084.

    Google Scholar 

  32. The GUSTO Angiographic Investigations. The effect of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329: 1615–1622.

    Google Scholar 

  33. Cannon CP, McCabe CA, Diver DJ, et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1994;24:1602–1610.

    Google Scholar 

  34. Zarich SW, Kowalchuk GJ, Weaver MD, et al. Sequential combination thrombolytic therapy for acute myocardial infarction: Results of the pro-urokinase and t-PA enhancement of thrombolysis (PATENT) trial. J Am Coll Cardiol 1995;26:374–379.

    Google Scholar 

  35. Bode C, Schuler G, Schonermark S, et al. Intravenous thrombolytic therapy with a combination single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction. Circulation 1990;81:907–913.

    Google Scholar 

  36. Kirshenbaum JM, Bahr RD, Flaherty JT, et al. Clot selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. Am J Cardiol 1991;68:1564–1569.

    Google Scholar 

  37. Van de Werf F. Thrombolysis for acute myocardial infarction. Haemostasis 1994;24:65–68.

    Google Scholar 

  38. The GREAT Group. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1994;23:1–5.

    Google Scholar 

  39. Weaver MD. Time to thrombolytic treatment: Factors affecting delay and their influence on outcome. J Am Coll Cardiol 1995;25(Suppl. 7):3S–9S.

    Google Scholar 

  40. Hennekens CH, O'Donnell CJ, Ridker PM, Marder V. Current issues concerning thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1995;25(Suppl. 7): 18S–22S.

    Google Scholar 

  41. Brouwer MA, Martin JS, Maynard C, Wirkus M, Litwin PE, Verheugt FWA, Weaver WD. Influence of early prehospital thrombolysis on mortality and event-free survival (the Myocardial Infarction Triage and Intervention [MITI] randomized trial). Am J Cardiol 1996;78:497–502.

    Google Scholar 

  42. Grijscels EWM, Bonten MJM, Lenderink T, et al. Pre-hospital thrombolytic therapy with either alteplase or streptokinase. Practical applications, complications and long-term results in 529 patients. Eur Heart J 1995;16:1833–1838.

    Google Scholar 

  43. Maksimenko AV. Complicated simplfication of dosage regimen for plasminogen activators. Ann NY Acad Sci 1996;799:139–145.

    Google Scholar 

  44. Wilcox RG. Coronary thrombolysis: Round two and beyond. Br Heart J 1991;65:175–176.

    Google Scholar 

  45. Rentrop KP. Restoration of anterograde flow in acute myocardial infarction: The first 15 years. J Am Coll Cardiol 1995;25(Suppl. 7):1S–2S.

    Google Scholar 

  46. Hennekens CA, Albert CM, Godfriend SL, Casiano JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction—evidence from clinical trials. N Engl J Med 1996;335:1660–1667.

    Google Scholar 

  47. Kawai C, Yui Y, Hosoda S, et al. A prospective, randomized double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: Comparison with native t-PA. J Am Coll Cardiol 1997;29:1447–1453.

    Google Scholar 

  48. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI). 10A doseranging trial. Circulation 1997;95:351–356.

    Google Scholar 

  49. Larson GR, Timony GA, Horgan PG, et al. Protein engineering of novel plasminogen activators with increased thrombolytic patency in rabbits relative to activase. J Biol Chem 1991;266:8156–8161.

    Google Scholar 

  50. Smalling RW. Molecular biology of plasminogen activators: What are the clinical implications of drug design? Am J Cardiol 1996;78(Suppl. 12A):2–7.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Biochemical Engineering, Department of Biotechnology, Institute of Experimental Cardiology, Russian Cardiology Research Center, Moscow, Russia

    Alexander V. Maksimenko & Elena G. Tischenko

Authors
  1. Alexander V. Maksimenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena G. Tischenko
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maksimenko, A.V., Tischenko, E.G. New Thrombolytic Strategy: Bolus Administration of tPA and Urokinase-Fibrinogen Conjugate. J Thromb Thrombolysis 7, 307–312 (1999). https://doi.org/10.1023/A:1008939428688

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008939428688

Search

Navigation